Esaxerenone: First Global Approval
Esaxerenone: First Global Approval
复制标题
DOI：
10.1007/s40265-019-01073-5
复制
发表时间：
2019-03-01
期刊：
影响因子：
11.5
通讯作者：
Duggan, Sean
中科院分区：
文献类型：
--
作者：
Duggan, Sean
Esaxerenone（MINNEBRO（TM））是一种新型的口服、非甾体、选择性盐皮质激素受体阻滞剂，由Daiichi Sankyo开发，用于治疗高血压和糖尿病肾病。2019年1月，基于在日本进行的原发性高血压患者III期试验的积极结果，依沙酮在日本获得了治疗高血压的上市批准。这篇文章总结了依沙色酮开发过程中的里程碑，导致这一全球首个批准用于治疗高血压。
Esaxerenone (MINNEBRO (TM))-a novel oral, non-steroidal, selective mineralocorticoid receptor blocker-is being developed by Daiichi Sankyo for the treatment of hypertension and diabetic nephropathies. In January 2019, based on positive results from a phase III trial conducted in Japan in patients with essential hypertension, esaxerenone received marketing approval in Japan for the treatment of hypertension. This article summarizes the milestones in the development of esaxerenone leading to this first global approval for the treatment of hypertension.